All In Biotech

Drug Trial Radar · NCT07914062

PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates

PRECISION-E2 Study is a Prospective Genomic Guided Precision Medicine Phase IIa, Randomized, Placebo Controlled Clinical Study in Women With Moderate to Severe Pain Associated With Symptomatic Endometriosis in UAE.

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Antev Ltd.Industry
Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 19 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PRECISION-E2 is a Phase IIa randomized, placebo-controlled study evaluating the pharmacodynamic profile, safety and tolerability of teverelix in premenopausal women with moderate-to-severe pain associated with endometriosis in the United Arab Emirates. The study will characterize the magnitude and duration of estradiol suppression following a single administration of teverelix and evaluate dose and route of administration, including subcutaneous and intramuscular administration, to inform subsequent clinical development. The study also incorporates a prospective precision medicine component designed to explore associations between genomic variation and pharmacodynamic and clinical response to teverelix. In participants enrolled in the Emirati Genome Program, genomic data will be integrated with hormonal, pharmacokinetic and clinical outcomes to investigate potential biological determinants of treatment response.

Conditions

  • Endometriosis Pelvic
  • Endometriosis Ovaries
  • Premenopausal
  • Endometriosis (Diagnosis)
  • Dysmenorrhoea
  • Dyspareunia (Female)

Interventions

  • Teverelix DPDrug

    Single dose at Day 1 of 60 mg injection SC

  • Teverelix DPDrug

    Single dose at Day 1 of 90 mg injection SC.

  • Teverelix DPDrug

    Single dose at Day 1 of 90 mg injection IM

  • Teverelix DP PlaceboDrug

    Single dose at Day 1 of placebo injection SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Serum Estradiol Maintained Within 20-50 pg/mL for at Least 14 Consecutive DaysTime frame: From Day 1 to Day 197

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.